Circulating microparticles as indicators of peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is associated with high mortality and morbidity. Endothelial damage involving cathepsin-D to form a 16 kDa prolactin (PRL) peptide is pathogenetically relevant. Inhibiting PRL peptide with bromocriptine has yielded promising results. We investigated whether micropart...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2012-06, Vol.33 (12), p.1469-1479 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1479 |
|---|---|
| container_issue | 12 |
| container_start_page | 1469 |
| container_title | European heart journal |
| container_volume | 33 |
| creator | WALENTA, Katrin SCHWARZ, Viktoria SCHIRMER, Stephan H KINDERMANN, Ingrid FRIEDRICH, Erik B SOLOMAYER, Erich Franz SLIWA, Karen LABIDI, Saida HILFIKER-KLEINER, Denise BÖHM, Michael |
| description | Peripartum cardiomyopathy (PPCM) is associated with high mortality and morbidity. Endothelial damage involving cathepsin-D to form a 16 kDa prolactin (PRL) peptide is pathogenetically relevant. Inhibiting PRL peptide with bromocriptine has yielded promising results. We investigated whether microparticles (MPs) can be quantified in serum as markers for diagnosis and treatment effects in PPCM.
Patients with PPCM were compared with age-matched healthy post-partum women (PPCTR), healthy pregnant women (PCTR), healthy non-pregnant women (NPCTR), patients with ischaemic cardiomyopathy (ICM), patients with stable coronary artery disease (CAD) and healthy controls (HCTR). Peripartum cardiomyopathy treated with bromocriptine (PPCM-BR) and with PPCM without bromocriptine-treatment as control (PPCM-BRCTR) were compared. Microparticles were determined by flow cytometry. Endothelial MPs (EMPs) were elevated in PPCM compared with PPCTR, PCTR, and NPCTR, each P< 0.001. They were significantly elevated compared with ICM, CAD, and HCTR (P< 0.001). Pregnancy (PCTR) exhibited only slight increases vs. ICM, CAD, NPCTR, and HCTR. The increase in PPCM was due to an increase of activated but not apoptotic EMPs. Platelet-derived microparticles were highly increased in PPCM compared with ICM (P< 0.001) but 9.3 ± 4.4-fold compared with CAD (P< 0.001). In NPCTR (P< 0.001) compared with NPCTR, the increase was 5.9 ± 1.7-fold (P< 0.001). Microparticles generated from monocytes (MMPs) were increased 2.4 ± 1.8-fold in PPCM compared with PCTR (P< 0.001) and 4.8 ± 3.6-fold compared with CAD (P< 0.001), whereas leucocyte MPs (LMPs) were not significantly elevated. Endothelial microparticles were significantly reduced in PPCM treated additionally with bromocriptine compared with PPCM treated only with heart failure therapy (P< 0.001).
Microparticle profiles may in long-term distinguish PPCM from normal pregnancy, heart failure, and vascular diseases and might be a diagnostic marker related to the pathomechanism of PPCM. |
| doi_str_mv | 10.1093/eurheartj/ehr485 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020831272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020831272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-1af2198789370312493deeb669d6179e8a6f0f870244d80eda525f280001d4393</originalsourceid><addsrcrecordid>eNpFkMtLAzEQh4MotlbvnmQvgpe1eWyyyVFKfUDBi4K3JU0mNmVfJruH_vemtFbmMIf55mPmh9AtwY8EKzaHMWxAh2E7h00oJD9DU8IpzZUo-DmaYqJ4LoT8mqCrGLcYYymIuEQTShkuC0GmaLnwwYy1Hnz7nTXehK5PPm9qiJmOmW-tN3roQsw6l_UQ_H48NpnRwfqu2SV82Oyu0YXTdYSbY5-hz-flx-I1X72_vC2eVrlhJRlyoh0lSpZSsRIzQgvFLMBaCGUFKRVILRx2ssS0KKzEYDWn3FGZDie2YIrN0MPB24fuZ4Q4VI2PBupat9CNsSKYYpnEJU0oPqDppRgDuKoPvtFhl6BqH151Cq86hJdW7o72cd2APS38pZWA-yOgo9G1C7o1Pv5zXHFGUv0Csy96-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020831272</pqid></control><display><type>article</type><title>Circulating microparticles as indicators of peripartum cardiomyopathy</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>WALENTA, Katrin ; SCHWARZ, Viktoria ; SCHIRMER, Stephan H ; KINDERMANN, Ingrid ; FRIEDRICH, Erik B ; SOLOMAYER, Erich Franz ; SLIWA, Karen ; LABIDI, Saida ; HILFIKER-KLEINER, Denise ; BÖHM, Michael</creator><creatorcontrib>WALENTA, Katrin ; SCHWARZ, Viktoria ; SCHIRMER, Stephan H ; KINDERMANN, Ingrid ; FRIEDRICH, Erik B ; SOLOMAYER, Erich Franz ; SLIWA, Karen ; LABIDI, Saida ; HILFIKER-KLEINER, Denise ; BÖHM, Michael</creatorcontrib><description><![CDATA[Peripartum cardiomyopathy (PPCM) is associated with high mortality and morbidity. Endothelial damage involving cathepsin-D to form a 16 kDa prolactin (PRL) peptide is pathogenetically relevant. Inhibiting PRL peptide with bromocriptine has yielded promising results. We investigated whether microparticles (MPs) can be quantified in serum as markers for diagnosis and treatment effects in PPCM.
Patients with PPCM were compared with age-matched healthy post-partum women (PPCTR), healthy pregnant women (PCTR), healthy non-pregnant women (NPCTR), patients with ischaemic cardiomyopathy (ICM), patients with stable coronary artery disease (CAD) and healthy controls (HCTR). Peripartum cardiomyopathy treated with bromocriptine (PPCM-BR) and with PPCM without bromocriptine-treatment as control (PPCM-BRCTR) were compared. Microparticles were determined by flow cytometry. Endothelial MPs (EMPs) were elevated in PPCM compared with PPCTR, PCTR, and NPCTR, each P< 0.001. They were significantly elevated compared with ICM, CAD, and HCTR (P< 0.001). Pregnancy (PCTR) exhibited only slight increases vs. ICM, CAD, NPCTR, and HCTR. The increase in PPCM was due to an increase of activated but not apoptotic EMPs. Platelet-derived microparticles were highly increased in PPCM compared with ICM (P< 0.001) but 9.3 ± 4.4-fold compared with CAD (P< 0.001). In NPCTR (P< 0.001) compared with NPCTR, the increase was 5.9 ± 1.7-fold (P< 0.001). Microparticles generated from monocytes (MMPs) were increased 2.4 ± 1.8-fold in PPCM compared with PCTR (P< 0.001) and 4.8 ± 3.6-fold compared with CAD (P< 0.001), whereas leucocyte MPs (LMPs) were not significantly elevated. Endothelial microparticles were significantly reduced in PPCM treated additionally with bromocriptine compared with PPCM treated only with heart failure therapy (P< 0.001).
Microparticle profiles may in long-term distinguish PPCM from normal pregnancy, heart failure, and vascular diseases and might be a diagnostic marker related to the pathomechanism of PPCM.]]></description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehr485</identifier><identifier>PMID: 22307461</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Analysis of Variance ; Biological and medical sciences ; Biomarkers ; Bromocriptine - therapeutic use ; Cardiology. Vascular system ; Cardiomyopathies - drug therapy ; Cardiomyopathies - pathology ; Case-Control Studies ; Cell-Derived Microparticles - pathology ; Female ; Flow Cytometry ; Heart ; Heart failure, cardiogenic pulmonary edema, cardiac enlargement ; Hormone Antagonists - therapeutic use ; Humans ; Medical sciences ; Myocarditis. Cardiomyopathies ; Pregnancy ; Puerperal Disorders - drug therapy ; Puerperal Disorders - pathology</subject><ispartof>European heart journal, 2012-06, Vol.33 (12), p.1469-1479</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-1af2198789370312493deeb669d6179e8a6f0f870244d80eda525f280001d4393</citedby><cites>FETCH-LOGICAL-c371t-1af2198789370312493deeb669d6179e8a6f0f870244d80eda525f280001d4393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25953131$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22307461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WALENTA, Katrin</creatorcontrib><creatorcontrib>SCHWARZ, Viktoria</creatorcontrib><creatorcontrib>SCHIRMER, Stephan H</creatorcontrib><creatorcontrib>KINDERMANN, Ingrid</creatorcontrib><creatorcontrib>FRIEDRICH, Erik B</creatorcontrib><creatorcontrib>SOLOMAYER, Erich Franz</creatorcontrib><creatorcontrib>SLIWA, Karen</creatorcontrib><creatorcontrib>LABIDI, Saida</creatorcontrib><creatorcontrib>HILFIKER-KLEINER, Denise</creatorcontrib><creatorcontrib>BÖHM, Michael</creatorcontrib><title>Circulating microparticles as indicators of peripartum cardiomyopathy</title><title>European heart journal</title><addtitle>Eur Heart J</addtitle><description><![CDATA[Peripartum cardiomyopathy (PPCM) is associated with high mortality and morbidity. Endothelial damage involving cathepsin-D to form a 16 kDa prolactin (PRL) peptide is pathogenetically relevant. Inhibiting PRL peptide with bromocriptine has yielded promising results. We investigated whether microparticles (MPs) can be quantified in serum as markers for diagnosis and treatment effects in PPCM.
Patients with PPCM were compared with age-matched healthy post-partum women (PPCTR), healthy pregnant women (PCTR), healthy non-pregnant women (NPCTR), patients with ischaemic cardiomyopathy (ICM), patients with stable coronary artery disease (CAD) and healthy controls (HCTR). Peripartum cardiomyopathy treated with bromocriptine (PPCM-BR) and with PPCM without bromocriptine-treatment as control (PPCM-BRCTR) were compared. Microparticles were determined by flow cytometry. Endothelial MPs (EMPs) were elevated in PPCM compared with PPCTR, PCTR, and NPCTR, each P< 0.001. They were significantly elevated compared with ICM, CAD, and HCTR (P< 0.001). Pregnancy (PCTR) exhibited only slight increases vs. ICM, CAD, NPCTR, and HCTR. The increase in PPCM was due to an increase of activated but not apoptotic EMPs. Platelet-derived microparticles were highly increased in PPCM compared with ICM (P< 0.001) but 9.3 ± 4.4-fold compared with CAD (P< 0.001). In NPCTR (P< 0.001) compared with NPCTR, the increase was 5.9 ± 1.7-fold (P< 0.001). Microparticles generated from monocytes (MMPs) were increased 2.4 ± 1.8-fold in PPCM compared with PCTR (P< 0.001) and 4.8 ± 3.6-fold compared with CAD (P< 0.001), whereas leucocyte MPs (LMPs) were not significantly elevated. Endothelial microparticles were significantly reduced in PPCM treated additionally with bromocriptine compared with PPCM treated only with heart failure therapy (P< 0.001).
Microparticle profiles may in long-term distinguish PPCM from normal pregnancy, heart failure, and vascular diseases and might be a diagnostic marker related to the pathomechanism of PPCM.]]></description><subject>Adult</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Biomarkers</subject><subject>Bromocriptine - therapeutic use</subject><subject>Cardiology. Vascular system</subject><subject>Cardiomyopathies - drug therapy</subject><subject>Cardiomyopathies - pathology</subject><subject>Case-Control Studies</subject><subject>Cell-Derived Microparticles - pathology</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Heart</subject><subject>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</subject><subject>Hormone Antagonists - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Pregnancy</subject><subject>Puerperal Disorders - drug therapy</subject><subject>Puerperal Disorders - pathology</subject><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtLAzEQh4MotlbvnmQvgpe1eWyyyVFKfUDBi4K3JU0mNmVfJruH_vemtFbmMIf55mPmh9AtwY8EKzaHMWxAh2E7h00oJD9DU8IpzZUo-DmaYqJ4LoT8mqCrGLcYYymIuEQTShkuC0GmaLnwwYy1Hnz7nTXehK5PPm9qiJmOmW-tN3roQsw6l_UQ_H48NpnRwfqu2SV82Oyu0YXTdYSbY5-hz-flx-I1X72_vC2eVrlhJRlyoh0lSpZSsRIzQgvFLMBaCGUFKRVILRx2ssS0KKzEYDWn3FGZDie2YIrN0MPB24fuZ4Q4VI2PBupat9CNsSKYYpnEJU0oPqDppRgDuKoPvtFhl6BqH151Cq86hJdW7o72cd2APS38pZWA-yOgo9G1C7o1Pv5zXHFGUv0Csy96-Q</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>WALENTA, Katrin</creator><creator>SCHWARZ, Viktoria</creator><creator>SCHIRMER, Stephan H</creator><creator>KINDERMANN, Ingrid</creator><creator>FRIEDRICH, Erik B</creator><creator>SOLOMAYER, Erich Franz</creator><creator>SLIWA, Karen</creator><creator>LABIDI, Saida</creator><creator>HILFIKER-KLEINER, Denise</creator><creator>BÖHM, Michael</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Circulating microparticles as indicators of peripartum cardiomyopathy</title><author>WALENTA, Katrin ; SCHWARZ, Viktoria ; SCHIRMER, Stephan H ; KINDERMANN, Ingrid ; FRIEDRICH, Erik B ; SOLOMAYER, Erich Franz ; SLIWA, Karen ; LABIDI, Saida ; HILFIKER-KLEINER, Denise ; BÖHM, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-1af2198789370312493deeb669d6179e8a6f0f870244d80eda525f280001d4393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Biomarkers</topic><topic>Bromocriptine - therapeutic use</topic><topic>Cardiology. Vascular system</topic><topic>Cardiomyopathies - drug therapy</topic><topic>Cardiomyopathies - pathology</topic><topic>Case-Control Studies</topic><topic>Cell-Derived Microparticles - pathology</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Heart</topic><topic>Heart failure, cardiogenic pulmonary edema, cardiac enlargement</topic><topic>Hormone Antagonists - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Pregnancy</topic><topic>Puerperal Disorders - drug therapy</topic><topic>Puerperal Disorders - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WALENTA, Katrin</creatorcontrib><creatorcontrib>SCHWARZ, Viktoria</creatorcontrib><creatorcontrib>SCHIRMER, Stephan H</creatorcontrib><creatorcontrib>KINDERMANN, Ingrid</creatorcontrib><creatorcontrib>FRIEDRICH, Erik B</creatorcontrib><creatorcontrib>SOLOMAYER, Erich Franz</creatorcontrib><creatorcontrib>SLIWA, Karen</creatorcontrib><creatorcontrib>LABIDI, Saida</creatorcontrib><creatorcontrib>HILFIKER-KLEINER, Denise</creatorcontrib><creatorcontrib>BÖHM, Michael</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WALENTA, Katrin</au><au>SCHWARZ, Viktoria</au><au>SCHIRMER, Stephan H</au><au>KINDERMANN, Ingrid</au><au>FRIEDRICH, Erik B</au><au>SOLOMAYER, Erich Franz</au><au>SLIWA, Karen</au><au>LABIDI, Saida</au><au>HILFIKER-KLEINER, Denise</au><au>BÖHM, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating microparticles as indicators of peripartum cardiomyopathy</atitle><jtitle>European heart journal</jtitle><addtitle>Eur Heart J</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>33</volume><issue>12</issue><spage>1469</spage><epage>1479</epage><pages>1469-1479</pages><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract><![CDATA[Peripartum cardiomyopathy (PPCM) is associated with high mortality and morbidity. Endothelial damage involving cathepsin-D to form a 16 kDa prolactin (PRL) peptide is pathogenetically relevant. Inhibiting PRL peptide with bromocriptine has yielded promising results. We investigated whether microparticles (MPs) can be quantified in serum as markers for diagnosis and treatment effects in PPCM.
Patients with PPCM were compared with age-matched healthy post-partum women (PPCTR), healthy pregnant women (PCTR), healthy non-pregnant women (NPCTR), patients with ischaemic cardiomyopathy (ICM), patients with stable coronary artery disease (CAD) and healthy controls (HCTR). Peripartum cardiomyopathy treated with bromocriptine (PPCM-BR) and with PPCM without bromocriptine-treatment as control (PPCM-BRCTR) were compared. Microparticles were determined by flow cytometry. Endothelial MPs (EMPs) were elevated in PPCM compared with PPCTR, PCTR, and NPCTR, each P< 0.001. They were significantly elevated compared with ICM, CAD, and HCTR (P< 0.001). Pregnancy (PCTR) exhibited only slight increases vs. ICM, CAD, NPCTR, and HCTR. The increase in PPCM was due to an increase of activated but not apoptotic EMPs. Platelet-derived microparticles were highly increased in PPCM compared with ICM (P< 0.001) but 9.3 ± 4.4-fold compared with CAD (P< 0.001). In NPCTR (P< 0.001) compared with NPCTR, the increase was 5.9 ± 1.7-fold (P< 0.001). Microparticles generated from monocytes (MMPs) were increased 2.4 ± 1.8-fold in PPCM compared with PCTR (P< 0.001) and 4.8 ± 3.6-fold compared with CAD (P< 0.001), whereas leucocyte MPs (LMPs) were not significantly elevated. Endothelial microparticles were significantly reduced in PPCM treated additionally with bromocriptine compared with PPCM treated only with heart failure therapy (P< 0.001).
Microparticle profiles may in long-term distinguish PPCM from normal pregnancy, heart failure, and vascular diseases and might be a diagnostic marker related to the pathomechanism of PPCM.]]></abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22307461</pmid><doi>10.1093/eurheartj/ehr485</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2012-06, Vol.33 (12), p.1469-1479 |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1020831272 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Analysis of Variance Biological and medical sciences Biomarkers Bromocriptine - therapeutic use Cardiology. Vascular system Cardiomyopathies - drug therapy Cardiomyopathies - pathology Case-Control Studies Cell-Derived Microparticles - pathology Female Flow Cytometry Heart Heart failure, cardiogenic pulmonary edema, cardiac enlargement Hormone Antagonists - therapeutic use Humans Medical sciences Myocarditis. Cardiomyopathies Pregnancy Puerperal Disorders - drug therapy Puerperal Disorders - pathology |
| title | Circulating microparticles as indicators of peripartum cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A43%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20microparticles%20as%20indicators%20of%20peripartum%20cardiomyopathy&rft.jtitle=European%20heart%20journal&rft.au=WALENTA,%20Katrin&rft.date=2012-06-01&rft.volume=33&rft.issue=12&rft.spage=1469&rft.epage=1479&rft.pages=1469-1479&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehr485&rft_dat=%3Cproquest_cross%3E1020831272%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1020831272&rft_id=info:pmid/22307461&rfr_iscdi=true |